Search Login Register

Facial Hemiatrophy (Parry-Romberg Syndrome) Summary

Description: A syndrome characterized by slowly progressive unilateral atrophy of facial subcutaneous fat, muscle tissue, skin, cartilage, and bone. The condition typically progresses over a period of 2-10 years and then stabilizes.

Also Known As: Parry-Romberg Syndrome; Hemifacial Atrophy, Progressive; Hemifacial Atrophy; Progressive Facial Hemiatrophy; Progressive Hemifacial Atrophy Show All >>

Networked: 104 relevant articles (6 outcomes, 3 trials/studies) for this Disease

Key Drugs and Agents for Facial Hemiatrophy

Efficacy Chart >>
Drugs and Important Biological Agents (IBA) related to treatments:
  1. Steroids : 1 outcome in 1 result : IBA
  2. Dimethylpolysiloxanes (Dimethylpolysiloxane) : 1 outcome in 1 result : IBA
  3. Dapsone : 1 outcome in 1 result : FDA 3
  4. Autoantibodies : 1 study in 1 result : IBA
  5. Silicones : 7 results : IBA
  6. Retinaldehyde (Retinal) : 5 results : IBA
  7. Cosmetics : 4 results : IBA
  8. Fluorescein (Funduscein) : 3 results : FDA 3 Generic
  9. Antinuclear Antibodies : 2 results : IBA
  10. Antibodies : 2 results : IBA
Show All >>

Diseases Related to Facial Hemiatrophy

  1. Facial Asymmetry (Hemifacial Microsomia)
  2. Congenital Abnormalities (Deformity)
  3. Necrosis
  4. Facial Hemiatrophy (Parry-Romberg Syndrome)
  5. Localized Scleroderma (Morphea)
Show All >>

Key Therapies for Facial Hemiatrophy

Efficacy Chart >>
  1. Transplants (Transplant) : 4 outcomes in 20 results
  2. Transplantation (Transplant Recipients) : 1 outcome in 14 results
  3. Injections : 1 outcome in 5 results
  4. Sympathectomy (Sympathectomies) : 2 studies in 4 results
  5. Free Tissue Flaps : 16 results
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.